Peter Fekkes

Peter Fekkes is an accomplished professional in the field of biochemistry and drug discovery, currently serving as the Owner of Tulip Bioconsulting since January 2023. Fekkes has been an Advisor at Recursis since April 2019 and held the position of VP Drug Discovery at 54gene from July 2021 to October 2022. Prior experience includes leadership roles as VP of Discovery Bioscience at FogPharma and Head of New Targets Platform at HotSpot Therapeutics, Inc. Fekkes also contributed significantly to H3 Biomedicine in various executive capacities from February 2012 to January 2018 and has an extensive background at Novartis, where Fekkes served as Head of the Open Access Medium Throughput Screening Lab and Lab Head of the High Throughput Screening Group. Early career positions include experiences as a Senior Scientist at SRU Biosystems and a Scientist at Phylos. Fekkes earned a PhD and an MS in Biology from the University of Groningen.